757.18
price up icon0.38%   2.83
pre-market  시장 영업 전:  759.00   1.82   +0.24%
loading
전일 마감가:
$754.35
열려 있는:
$755.57
하루 거래량:
2.44M
Relative Volume:
0.69
시가총액:
$680.08B
수익:
$45.04B
순이익/손실:
$10.59B
주가수익비율:
64.66
EPS:
11.71
순현금흐름:
$414.30M
1주 성능:
+4.26%
1개월 성능:
-6.92%
6개월 성능:
-17.10%
1년 성능:
+0.85%
1일 변동 폭
Value
$751.49
$765.31
1주일 범위
Value
$689.00
$765.31
52주 변동 폭
Value
$677.09
$972.53

일라이 릴리 Stock (LLY) Company Profile

Name
명칭
Lilly Eli Co
Name
전화
(317) 276-2000
Name
주소
LILLY CORPORATE CTR, INDIANAPOLIS, IN
Name
직원
47,000
Name
트위터
@LillyPad
Name
다음 수익 날짜
2024-10-30
Name
최신 SEC 제출 서류
Name
LLY's Discussions on Twitter

LLY을(를) 다른 주식과 비교

주식 가격 시가총액 매출 순이익 현금흐름 주당 순 이익
Drug Manufacturers - General icon
LLY
Lilly Eli Co
757.18 680.08B 45.04B 10.59B 414.30M 11.71
Drug Manufacturers - General icon
JNJ
Johnson Johnson
153.62 344.63B 88.82B 14.07B 18.06B 5.79
Drug Manufacturers - General icon
ABBV
Abbvie Inc
176.80 312.76B 56.33B 4.28B 17.83B 2.40
Drug Manufacturers - General icon
NVO
Novo Nordisk Adr
64.49 286.27B 42.09B 14.65B 10.11B 3.2833
Drug Manufacturers - General icon
NVS
Novartis Ag Adr
109.93 217.12B 51.72B 11.94B 13.81B 5.88

일라이 릴리 Stock (LLY) Upgrades & Downgrades

날짜 액션 분석자 등급 변경
2024-12-10 재개 BofA Securities Buy
2024-11-15 개시 Wolfe Research Outperform
2024-10-17 개시 Bernstein Outperform
2024-09-13 재개 Citigroup Buy
2024-08-12 업그레이드 Deutsche Bank Hold → Buy
2024-02-21 다운그레이드 DZ Bank Buy → Hold
2024-02-16 재확인 Morgan Stanley Overweight
2023-12-21 다운그레이드 Daiwa Securities Buy → Outperform
2023-11-09 개시 Deutsche Bank Hold
2023-10-20 재개 UBS Buy
2023-08-09 업그레이드 Jefferies Hold → Buy
2023-07-26 재확인 Citigroup Buy
2023-07-14 개시 HSBC Securities Buy
2023-05-24 재확인 BofA Securities Buy
2023-05-24 재확인 UBS Buy
2023-03-13 업그레이드 Wells Fargo Equal Weight → Overweight
2023-03-06 개시 Jefferies Hold
2023-02-15 다운그레이드 Societe Generale Hold → Sell
2022-11-18 개시 Credit Suisse Outperform
2022-09-22 업그레이드 UBS Neutral → Buy
2022-05-23 개시 SVB Leerink Outperform
2022-04-06 재개 Morgan Stanley Overweight
2022-03-10 개시 Daiwa Securities Outperform
2022-01-21 업그레이드 DZ Bank Hold → Buy
2022-01-03 재확인 Bernstein Mkt Perform
2021-12-17 개시 Goldman Neutral
2021-12-16 재확인 BMO Capital Markets Outperform
2021-12-16 재확인 BofA Securities Buy
2021-12-09 재개 Wells Fargo Equal Weight
2021-11-19 개시 BMO Capital Markets Outperform
2021-10-11 업그레이드 Berenberg Hold → Buy
2021-09-29 업그레이드 Citigroup Neutral → Buy
2021-08-05 업그레이드 DZ Bank Hold → Buy
2021-07-27 재개 Truist Buy
2021-06-24 재확인 Cantor Fitzgerald Overweight
2021-01-19 업그레이드 Mizuho Neutral → Buy
2020-12-10 업그레이드 Wolfe Research Peer Perform → Outperform
2020-11-10 재개 Bernstein Mkt Perform
2020-09-29 개시 Berenberg Hold
2020-09-03 업그레이드 Morgan Stanley Equal-Weight → Overweight
2020-06-16 업그레이드 Guggenheim Neutral → Buy
2020-04-21 다운그레이드 UBS Buy → Neutral
2020-04-09 다운그레이드 Morgan Stanley Overweight → Equal-Weight
2020-02-06 개시 Mizuho Neutral
2019-12-18 업그레이드 Morgan Stanley Equal-Weight → Overweight
2019-10-17 재개 BofA/Merrill Buy
2019-05-28 개시 Goldman Buy
2019-04-24 업그레이드 Edward Jones Hold → Buy
2019-04-11 다운그레이드 Guggenheim Buy → Neutral
2019-03-12 개시 JP Morgan Overweight
2019-01-23 개시 UBS Buy
2018-11-26 다운그레이드 Citigroup Buy → Neutral
2018-10-31 업그레이드 Credit Suisse Underperform → Neutral
2018-10-09 개시 Guggenheim Buy
2018-10-01 재확인 SunTrust Buy
2018-09-26 재개 JP Morgan Overweight
모두보기

일라이 릴리 주식(LLY)의 최신 뉴스

pulisher
Apr 15, 2025

Skye Bioscience's Obesity Candidate Shows 30% Weight Loss When Combined With Eli Lilly's Blockbuster Drug In Animal Models - Benzinga

Apr 15, 2025
pulisher
Apr 15, 2025

Eli Lilly's Mounjaro Launch Triggers Weight-Loss Drug Craze In India, Novo Nordisk Seeks To Move Up Wegovy Launch - Benzinga

Apr 15, 2025
pulisher
Apr 15, 2025

Is Eli Lilly and Company (LLY) the Best Pharma Stock to Buy for Long Term Growth? - Insider Monkey

Apr 15, 2025
pulisher
Apr 15, 2025

Bernstein raises Eli Lilly stock price target to $1,100 By Investing.com - Investing.com India

Apr 15, 2025
pulisher
Apr 15, 2025

Bernstein raises Eli Lilly stock price target to $1,100 - Investing.com

Apr 15, 2025
pulisher
Apr 15, 2025

HHS Rejects Amgen, Lilly Fight of Clinics in Drug Discount Plan - Bloomberg Law News

Apr 15, 2025
pulisher
Apr 15, 2025

Down 71%, Should You Buy the Dip on Viking Therapeutics Stock? - The Motley Fool

Apr 15, 2025
pulisher
Apr 15, 2025

Skye Bioscience Demonstrates Over 30% Weight Loss With Nimacimab And Tirzepatide Combination In Preclinical Model - MarketScreener

Apr 15, 2025
pulisher
Apr 15, 2025

Eli Lilly and Company (LLY): One of the High Growth Forever Dividend Stocks to Invest In - Yahoo Finance

Apr 15, 2025
pulisher
Apr 15, 2025

Eli Lilly (LLY) Sees Price Target Reduced by Guggenheim Ahead of Earnings | LLY Stock News - GuruFocus

Apr 15, 2025
pulisher
Apr 14, 2025

Eli Lilly issues warning for Australia as Trump signals pharma tariffs - AFR

Apr 14, 2025
pulisher
Apr 14, 2025

Eli Lilly's Mounjaro launch in India ignites wave of weight-loss enquiries - Reuters

Apr 14, 2025
pulisher
Apr 14, 2025

Verve’s shares jump by more than 26% on Lilly-partnered gene therapy data - Pharmaceutical Technology

Apr 14, 2025
pulisher
Apr 14, 2025

Why Eli Lilly, Novo Nordisk, and Viking Therapeutics Stocks All Popped Today - The Motley Fool

Apr 14, 2025
pulisher
Apr 14, 2025

Jim Cramer on Eli Lilly and Company (LLY): “The Fastest Factory I’ve Ever Seen” - Insider Monkey

Apr 14, 2025
pulisher
Apr 14, 2025

Eli Lilly Stock: A Deep Dive Into Analyst Perspectives (7 Ratings) - Benzinga

Apr 14, 2025
pulisher
Apr 14, 2025

Eli Lilly (LLY) Challenges OrderlyMeds Over Compounded Tirzepati - GuruFocus

Apr 14, 2025
pulisher
Apr 14, 2025

Eli Lilly price target lowered to $928 from $973 at Guggenheim - TipRanks

Apr 14, 2025
pulisher
Apr 14, 2025

Verve's 2nd swing at PCSK9 editing yields clean safety profile, teeing up Lilly opt-in decision - Fierce Biotech

Apr 14, 2025
pulisher
Apr 13, 2025

Eli Lilly (LLY) Shows Strong Revenue Growth and Strategic Expans - GuruFocus

Apr 13, 2025
pulisher
Apr 13, 2025

Eli Lilly (LLY) Boosts U.S. Manufacturing with $50 Billion Inves - GuruFocus

Apr 13, 2025
pulisher
Apr 13, 2025

Eli Lilly Stock: Some Big News Is Incoming (NYSE:LLY) - Seeking Alpha

Apr 13, 2025
pulisher
Apr 13, 2025

Eli Lilly's Obesity Drug Maintains Weight Loss for Three Years - MarketScreener

Apr 13, 2025
pulisher
Apr 12, 2025

Notable analyst calls this week: Apple, Eli Lilly and Verizon stocks among top picks - Seeking Alpha

Apr 12, 2025
pulisher
Apr 11, 2025

Novo, Lilly Patent Moves Keep GLP-1 Prices High, Report Says (3) - Bloomberg Law News

Apr 11, 2025
pulisher
Apr 11, 2025

Lilly’s Zepbound Keeps Weight Off for Three Years, Study Finds - Bloomberg

Apr 11, 2025
pulisher
Apr 11, 2025

Why Eli Lilly and Company (LLY) Is the Best Medical Stock to Buy According to Billionaires - Insider Monkey

Apr 11, 2025
pulisher
Apr 11, 2025

Eli Lilly Drops $1.57B Bombshell--And Wall Street Shrugs It Off - Yahoo Finance

Apr 11, 2025
pulisher
Apr 11, 2025

Eli Lilly Reverses Its Recent Run On Market Malaise. Is It A Sell? - Investor's Business Daily

Apr 11, 2025
pulisher
Apr 11, 2025

Compounding pharmacy says Eli Lilly’s cease and desist letter means “nothing” - Sherwood News

Apr 11, 2025
pulisher
Apr 11, 2025

OrderlyMeds Defies Eli Lilly (LLY) Cease-and-Desist Over Compoun - GuruFocus

Apr 11, 2025
pulisher
Apr 11, 2025

Eli Lilly (LLY) Anticipates Q1 2025 Earnings Impact from Researc - GuruFocus

Apr 11, 2025
pulisher
Apr 11, 2025

Personalized Medicine Market Forecast Report and Company Analysis 2025-2033 Featuring Abbott, GE, Aadi Bioscience, Illumina, QIAGEN, Eli Lilly and Co, Takeda, AbbVie, F. Hoffmann-La RocheResearchAndMarkets.com | FinancialContent - FinancialContent

Apr 11, 2025
pulisher
Apr 11, 2025

Novo Nordisk and Eli Lilly Bring Weight Loss Contest to India - outlookbusiness.com

Apr 11, 2025
pulisher
Apr 11, 2025

The Zacks Analyst Blog Highlights Eli Lilly, American Express, Thermo Fisher, Steel Partners and Oil-Dri - Yahoo Finance

Apr 11, 2025
pulisher
Apr 10, 2025

ITC Blocks Imports Of Copycats Of Eli Lilly Weight Loss Drug - Law360

Apr 10, 2025
pulisher
Apr 10, 2025

Top Research Reports for Eli Lilly, American Express & Thermo Fisher - Yahoo Finance

Apr 10, 2025
pulisher
Apr 10, 2025

Eli Lilly Estimates Q1 2025 Acquired IPR&D Charges Approximately $1.72 To EPS - MarketScreener

Apr 10, 2025
pulisher
Apr 10, 2025

Novo, Lilly Patent Moves Keep GLP-1 Prices High, Report Says (1) - Bloomberg Law News

Apr 10, 2025
pulisher
Apr 10, 2025

Behind the Scenes of Eli Lilly's Latest Options Trends - Benzinga

Apr 10, 2025
pulisher
Apr 10, 2025

GLP-1 Agonists Market Key Players Analysis- Eli Lilly and Company, Sanofi, AstraZeneca, Novo Nordisk. - openPR.com

Apr 10, 2025
pulisher
Apr 10, 2025

Q4 Earnings Highs And Lows: Eli Lilly (NYSE:LLY) Vs The Rest Of The Branded Pharmaceuticals Stocks - Yahoo Finance

Apr 10, 2025
pulisher
Apr 10, 2025

Lilly backs $41M investment in Longwood Fund spinout - The Business Journals

Apr 10, 2025
pulisher
Apr 09, 2025

FDA: Pharmacies' Bid To Keep Making Eli Lilly Drug Is 'Absurd' - Law360

Apr 09, 2025
pulisher
Apr 09, 2025

Eli Lilly and Company (LLY): One of the High Growth Dividend Paying Stocks to Invest in - Insider Monkey

Apr 09, 2025
pulisher
Apr 09, 2025

Trump-Powered Medicare Setback Adds Bullish Impetus for Eli Lilly & Co (LLY) Stock - markets.businessinsider.com

Apr 09, 2025
pulisher
Apr 09, 2025

Lobbying Update: $60,000 of ELI LILLY AND COMPANY lobbying was just disclosed - Nasdaq

Apr 09, 2025
pulisher
Apr 09, 2025

Eli Lilly & Co (LLY) Gets a Buy from Bank of America Securities - The Globe and Mail

Apr 09, 2025
pulisher
Apr 09, 2025

Top Stock Movers Now: Delta, Apple, Eli Lilly, and More - Investopedia

Apr 09, 2025
pulisher
Apr 09, 2025

Why Roche Holding, Eli Lilly, and AstraZeneca Stocks Dropped Today - The Motley Fool

Apr 09, 2025
pulisher
Apr 09, 2025

Eli Lilly & Company (LLY): Among Defensive Stocks Billionaire Ken Fisher Is Betting On - Insider Monkey

Apr 09, 2025

일라이 릴리 (LLY) 재무 분석

매출

loading

순이익

loading

현금흐름

loading

주당 순 이익

loading
drug_manufacturers_general JNJ
$153.62
price down icon 0.48%
$176.80
price down icon 1.28%
drug_manufacturers_general NVO
$64.49
price down icon 2.38%
drug_manufacturers_general NVS
$109.93
price up icon 0.43%
drug_manufacturers_general MRK
$78.39
price down icon 0.99%
자본화:     |  볼륨(24시간):